Drug profile · INN
alogliptin
NESINA
alogliptin (NESINA) is a dipeptidyl peptidase iv inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — alogliptin
- US status
- approved
- Class
- Alimentary tract and metabolism (A10)
- Route
- ORAL
- Patents
- 0
- Programs
- 14
- Data quality
- 0.89
Quick answer
alogliptin (NESINA) is a dipeptidyl peptidase iv inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dipeptidyl peptidase IV inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is alogliptin?
alogliptin (NESINA) is a dipeptidyl peptidase iv inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for alogliptin?
NESINA is a marketed brand name for alogliptin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of alogliptin?
alogliptin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.